Argenx : Negative phase II results in PC- POTS
>Discontinuation of programme in PC-POTS - Argenx announced negative results in the phase II ALPHA trial evaluating patients with post-Covid postural orthostatic tachycardia syndrome (PC-POTS). The study showed that the patients treated saw no clinically significant improvement relative to the placebo on the total score for Malmö POTS symptoms (MaPS) and COMPASS31 (the company provided no digital results). Argenx is to discontinue development of this indication a...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.